LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.3 USD 1.96% Market Closed
Market Cap: 34.2m USD

Intrinsic Value

LVTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one LVTX stock under the Base Case scenario is 2 USD. Compared to the current market price of 1.3 USD, LAVA Therapeutics NV is Undervalued by 35%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LVTX Intrinsic Value
2 USD
Undervaluation 35%
Intrinsic Value
Price
Base Case Scenario

Valuation History
LAVA Therapeutics NV

LVTX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for LVTX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about LVTX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about LAVA Therapeutics NV
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
LAVA Therapeutics NV

Current Assets 81.5m
Cash & Short-Term Investments 78.9m
Receivables 1m
Other Current Assets 1.6m
Non-Current Assets 1.8m
PP&E 1.7m
Other Non-Current Assets 114k
Efficiency

Free Cash Flow Analysis
LAVA Therapeutics NV

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
LAVA Therapeutics NV

Revenue
7.3m USD
Cost of Revenue
-154k USD
Gross Profit
7.2m USD
Operating Expenses
-35.2m USD
Operating Income
-28m USD
Other Expenses
397k USD
Net Income
-27.6m USD
Fundamental Scores

LVTX Profitability Score
Profitability Due Diligence

LAVA Therapeutics NV's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

28/100
Profitability
Score

LAVA Therapeutics NV's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

LVTX Solvency Score
Solvency Due Diligence

LAVA Therapeutics NV's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
61/100
Solvency
Score

LAVA Therapeutics NV's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LVTX Price Targets Summary
LAVA Therapeutics NV

Wall Street analysts forecast LVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LVTX is 2.21 USD with a low forecast of 1.52 USD and a high forecast of 3.15 USD.

Lowest
Price Target
1.52 USD
17% Upside
Average
Price Target
2.21 USD
70% Upside
Highest
Price Target
3.15 USD
142% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

LAVA Therapeutics NV
does not pay dividends
Shareholder Yield

Current shareholder yield for LVTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one LVTX stock?

The intrinsic value of one LVTX stock under the Base Case scenario is 2 USD.

Is LVTX stock undervalued or overvalued?

Compared to the current market price of 1.3 USD, LAVA Therapeutics NV is Undervalued by 35%.

Back to Top